Integra LifeSciences Holdings (IART)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 81,069 | 213,894 | 214,677 | 93,520 | 60,104 |
| Revenue | US$ in thousands | 1,486,360 | 1,506,670 | 1,533,950 | 1,298,690 | 1,461,480 |
| Pretax margin | 5.45% | 14.20% | 14.00% | 7.20% | 4.11% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $81,069K ÷ $1,486,360K
= 5.45%
Integra Lifesciences Holdings Corp's pretax margin has shown some fluctuations over the past five years. In 2023, the pretax margin decreased to 5.26% from 13.73% in 2022, reflecting a significant decline in profitability. This decrease may indicate challenges in managing costs or generating revenues efficiently. Comparing to the peak pretax margin of 13.92% in 2021, the 2023 pretax margin appears notably lower.
Furthermore, the pretax margin in 2023 is slightly above the one in 2020 (6.82%) and significantly higher than in 2019 (3.96%). This indicates that, despite the recent decline, the company has maintained a relatively improved level of profitability compared to the earlier years.
Overall, the trend in Integra Lifesciences Holdings Corp's pretax margin suggests variability in the company's ability to translate its sales into profits, highlighting the importance of closely monitoring and addressing factors affecting profitability.
Peer comparison
Dec 31, 2023